Related by context. All words. (Click for frequent words.) 81 myeloid blast 71 Ph + ALL 68 Ribavirin causes 68 phase Ph + 67 MCyR 67 blastic phase 67 hypophosphatemia 66 neutropenia dehydration dyspnea 66 dasatinib Sprycel ® 66 8mg/kg 65 peripheral sensory neuropathy 65 hypomagnesemia 65 severe oral mucositis 65 myeloid 65 4mg/kg 65 non splenectomized 65 Cutaneous T 65 severe neutropenia 64 metastatic malignant 64 leukemia AML 64 REYATAZ r arm 64 generalized edema 64 relapsed Acute Myeloid 64 Ph + CP 64 myelodysplastic myeloproliferative diseases 64 bone marrow reticulin deposition 64 cytogenetic responses 64 systemic anaplastic large 64 alanine aminotransferase 63 chronic myeloid 63 cutaneous T 63 leukemia CML 63 leukemia APL 63 elevated transaminases 63 #mg/m# [001] 63 Relapsed Refractory 63 hematologic toxicity 63 acute GvHD 63 achieved ACR# 63 refractory NSCLC 63 tumors GIST 63 leukemia ALL 62 HBeAg negative 62 delayed onset CINV 62 mg/m2/day 62 haematologic 62 aspartate aminotransferase AST 62 cytogenetic response 62 polycythemia vera essential thrombocythemia 62 non myeloid malignancies 62 refractory cutaneous T 62 essential thrombocythemia 62 tumor lysis syndrome 62 diagnosed Ph + 62 hyperphenylalaninemia HPA due 62 refractory chronic lymphocytic 62 Refractory Hodgkin Lymphoma 62 Kit CD# positive 62 hepatorenal syndrome 62 cell lymphoma CTCL 62 purpura ITP 62 mcg kg REBETOL 61 chronic immune thrombocytopenic 61 recurrent glioblastoma multiforme 61 stage IIIB 61 receiving INTRON 61 naïve HCV 61 essential thrombocythemia ET 61 Diffuse Large B 61 relapsed MM 61 refractory AML 61 papillary renal cell carcinoma 61 plus prednisone prednisolone 61 alanine aminotransferase ALT 61 Testosterone MDTS R 61 SGPT 61 lintuzumab SGN 61 SPRYCEL ® 61 neutropenic fever 61 Acute myelogenous leukemia 61 BCG refractory carcinoma 61 deep venous thromboses 61 #mg/m# [002] 61 Chronic ITP 61 leucopenia 61 hypokalemia 61 CYT# potent vascular disrupting 61 nucleoside naive 61 anthracycline taxane 61 lymphocytosis 61 Acute myeloid leukemia 61 ® lenalidomide 61 irinotecan containing 61 autoantibody positive 60 relapsed refractory multiple myeloma 60 dasatinib Sprycel 60 Toxicities 60 lopinavir r arm 60 mitoxantrone plus 60 humanized interleukin 6 60 metastatic GIST 60 diagnosed glioblastoma multiforme 60 biochemical relapse 60 complement inhibitor eculizumab 60 CML CP 60 nausea dizziness vomiting 60 Omacetaxine 60 Pharmacokinetics PK 60 Chronic lymphocytic leukemia CLL 60 Hypotension 60 Forodesine HCl 60 Gleevec resistant 60 nilotinib Tasigna ® 60 â ‰ ¥ 60 alfa 2a 60 iobenguane 60 achieved CCyR 60 cyclophosphamide methotrexate 60 dexamethasone Decadron 60 mcg BID 60 imatinib resistant 60 ALT normalization 60 plus methotrexate 60 ACTEMRA TM 60 Ph + CML 59 carcinoma mCRC 59 Peginterferon alfa 2b 59 VP# [004] 59 refractory chronic myeloid 59 leukemia CLL 59 mg TID 59 lenalidomide Revlimid R 59 cytopenias 59 advanced carcinoid 59 recurrent genital herpes 59 serum aminotransferase levels 59 mg/m2 dose 59 intravascular hemolysis 59 Relapsing Remitting Multiple Sclerosis 59 FUSILEV enhances 59 Decitabine 59 HBeAg positive 59 PNP inhibitor 59 doxorubicin cyclophosphamide 59 small lymphocytic lymphoma 59 weekly subcutaneous injections 59 EGFR HER2 59 metastatic malignant melanoma 59 Fludarabine 59 receptor tyrosine kinase inhibitor 59 Stage IIB 59 imatinib Gleevec ® 59 hypercalcemia 59 cetuximab Erbitux R 59 FOLFIRI alone 59 ribavirin therapy 59 #mg QD [002] 59 mg m² 59 progesterone receptor negative 59 non metastatic osteosarcoma 59 FOLFOX6 59 Amgen Neulasta ® 59 decompensated liver disease 59 HBeAg seroconversion 59 piperacillin tazobactam 59 Newly Diagnosed Multiple Myeloma 59 Ibritumomab Tiuxetan 59 aspartate aminotransferase 59 erlotinib Tarceva ® 59 severe renal impairment 59 idiopathic thrombocytopenic purpura ITP 59 post transplant lymphoproliferative 59 Folfox 59 primary hypercholesterolemia 59 Relapsed 59 lactate dehydrogenase 59 PEGylated anti 59 prior chemotherapy regimens 59 BARACLUDE ® 59 MGd 59 stage IIIb IV 59 Philadelphia Chromosome Positive 58 anemia neutropenia 58 saline placebo 58 serum prostate 58 interferon alfa 2a 58 refractory DLBCL 58 chronic myelogenous leukemia CML 58 imatinib therapy 58 immune thrombocytopenic purpura ITP 58 ALT elevation 58 EGFR TKI 58 receiving prophylactic anticoagulation 58 mg BID 58 TEAEs 58 liver enzymes ALT 58 adriamycin 58 recurrent VTE 58 aminotransferases 58 adjunctive ABILIFY 58 See CONTRAINDICATIONS 58 C1 INH deficiency 58 Bcr Abl T#I mutation 58 heavily pretreated 58 VELCADE melphalan 58 herpes zoster shingles 58 ug dose 58 febrile neutropenia 58 CCyR 58 relapsed CLL 58 pT3 58 genotype 1b 58 K ras mutations 58 beclomethasone dipropionate 58 Myelodysplastic Syndrome MDS 58 metastatic renal cell 58 HBeAg negative patients 58 NMIBC 58 osteosarcomas 58 tyrosine kinase inhibitor TKI 58 telaprevir dosed 58 mg q#h 58 de novo kidney transplant 58 cutaneous T cell 58 Follicular Lymphoma 58 reduce serum phosphate 58 certolizumab 58 lymphoma CTCL 58 Lupuzor ™ 58 Host Disease GvHD 58 Myelofibrosis 58 ara C 58 evaluating tivozanib 58 relapsed refractory 58 refractory CTCL 58 EXJADE 58 chronic GVHD 58 Sezary syndrome 58 CHOP chemotherapy 58 pmol liter 58 Ph + 58 systemic corticosteroid 58 epithelial ovarian 58 x ULN 58 log# copies mL 58 Neutropenia 58 PSADT 58 progression TTP 58 lymphoid malignancies 58 CMV seropositive 58 orally administered inhibitor 58 relapsed follicular lymphoma 58 torsade de pointes 58 log# IU mL 58 receiving immunosuppressive therapy 58 μg liter 58 leukopenia 58 huN# DM1 57 BCR ABL mutation 57 myelodysplastic syndrome MDS 57 Vidaza ® 57 elevated ALT 57 potentially hepatotoxic 57 cell acute lymphoblastic 57 cisplatin gemcitabine 57 Zometa hazard 57 urinary N telopeptide 57 mg QD 57 #mg BID [001] 57 receiving highly emetogenic 57 Cytarabine Liposome Injection 57 histologically confirmed 57 forodesine 57 response CCyR 57 adjunctive placebo 57 DLTs 57 steroid refractory ulcerative 57 recurrent NSCLC 57 resistant hormone refractory 57 unresectable recurrent 57 2 methoxyestradiol 57 taxane resistant 57 remission induction 57 oral methylnaltrexone 57 pegylated interferon alfa 2a 57 complete cytogenetic response 57 AGILECT R 57 treatment naive genotype 57 mitoxantrone chemotherapy 57 autoantibody levels 57 idiopathic thrombocytopenic purpura 57 aminotransferase elevations greater 57 ALT flares 57 lipid elevations 57 thyrotoxicosis 57 Gel repository corticotropin injection 57 NYHA Class II 57 umol L 57 biologic DMARD 57 dysplastic lesions 57 gastrointestinal stromal tumors GIST 57 D aspartate NMDA receptor 57 bevacizumab Avastin R 57 CR CRu 57 mg/m2 IV 57 platinum refractory 57 acute myeloid 57 Leukemia AML 57 refractory metastatic colorectal cancer 57 lactate dehydrogenase LDH 57 angiotensin analog 57 plasma uric acid 57 fallopian tube cancers 57 prolonged QT interval 57 transaminase 57 evaluable subjects 57 bacteriuria 57 advanced unresectable 57 chlorambucil 57 relapsed acute myelogenous 57 painful diabetic neuropathy 57 severe hypersensitivity reactions 57 transplantation HCT 57 ribavirin RBV 57 chronic plaque psoriasis 57 hepatocellular cancer 57 moderate renal impairment 57 PSA nadir 57 neurologic progression 57 mL/min/#.# m 2 57 epithelial tumors 57 Myelosuppression 57 histologic subtype 57 daunorubicin 57 HBsAg positive 57 severe exacerbations 57 dosing cohort 57 corticosteroid dose 57 NovoLog ® Mix 57 Chronic Myeloid Leukemia 57 treatment naïve genotype 57 KRAS mutations occur 57 dacarbazine DTIC 57 pheochromocytoma 57 serum phosphate 57 mcg kg 57 sunitinib Sutent ® 57 Chronic Lymphocytic Leukemia CLL 57 estramustine 57 tyrosine kinase inhibitors TKIs 57 partial remissions 57 anthracycline containing 57 generalized tonic clonic seizures 57 refractory CML 57 SCr 57 interferon ribavirin 56 % CI #.#-#.# [007] 56 transaminases 56 myeloproliferative diseases 56 Pegylated Interferon 56 infliximab monotherapy 56 recurrent metastatic 56 Soft Tissue Sarcoma 56 dose melphalan 56 CMV infection 56 downregulation 56 JAK2 V#F 56 bortezomib refractory 56 IAP inhibitor 56 atypical Hemolytic Uremic Syndrome 56 eosinophilic asthma 56 pyrimidine nucleoside analog 56 chronic HCV genotype 56 Thrombocytopenia 56 FOLFOX chemotherapy 56 plus gemcitabine 56 q#h 56 aminotransferase levels 56 keloid scarring 56 induce remission 56 oral vancomycin 56 FasL 56 fungoides 56 corticosteroids immunoglobulins 56 intravenous bolus 56 morphometric vertebral fractures 56 prokinetic agent 56 blood phenylalanine Phe 56 prednisone prednisolone 56 transaminase elevations 56 Treatment Naive Patients 56 CIN3 56 PEGINTRON TM 56 myeloproliferative disorder 56 achieved sustained virologic 56 achieved PASI 56 fallopian tube carcinoma 56 relapsed multiple myeloma 56 alkylating agent 56 -#.# log# 56 vincristine doxorubicin 56 metastatic CRC 56 mU liter 56 systemic ALCL 56 grade cervical intraepithelial 56 mcg mL 56 refractory multiple myeloma 56 biliary tract cancer 56 incidence ≥ 56 acetonide FA 56 external genital lesions 56 underwent surgical resection 56 pneumocystis carinii pneumonia 56 dose cohort 56 peginterferon alfa 56 primidone 56 mg/m2 56 patient derived xenografts 56 CIMZIA TM 56 IV metastatic melanoma 56 HES CEL 56 specific antigen PSA 56 oral antidiabetic medication 56 secondary hyperparathyroidism 56 castrate resistant prostate cancer 56 Peginterferon 56 Flu Cy 56 refractory acute promyelocytic 56 TTF Therapy 56 chronic myeloid leukemia CML 56 desvenlafaxine succinate 56 refractory gout 56 alvespimycin 56 flutamide 56 neutropenic patients 56 completely resected 56 unresectable tumors 56 irinotecan doxorubicin oxaliplatin paclitaxel 56 APTIVUS r 56 concomitant antibiotics 56 gastrointestinal stromal tumor GIST 56 randomized #:# 56 underwent resection 56 onset idiopathic hypogonadism 56 delayed CINV 56 generalized seizures 56 FluCAM 56 tumor necrosis 56 minimally symptomatic metastatic castrate 56 del 5q MDS 56 subependymal giant cell 56 hypoperfusion 56 ug ml 56 corticosteroid therapy 56 dapagliflozin plus 56 investigational oral inhibitor 56 golimumab CNTO 56 plus dexamethasone 56 Kinoid 56 acute myelogenous leukemia AML 56 CLL SLL 56 pegIFN 56 intratumoral 56 oral prodrug 56 xanthine oxidase inhibitor 56 non constipating irritable 56 administered subcutaneously 56 ipsilateral stroke 56 urothelial 56 allogeneic stem cell 56 mg kg dose 56 conventional DMARDs 56 venlafaxine XR 56 posterior uveitis 56 % Confidence Interval 56 sitaxsentan 56 gemcitabine Gemzar ® 56 mcg albinterferon alfa 2b 56 PegIFN RBV 56 CR nPR 56 colorectal carcinoma 56 unfavorable cytogenetics 56 rFSH 56 recurrent malignant glioma 56 EGFR expressing mCRC 56 receiving VICTRELIS 56 CIMZIA TM certolizumab pegol 56 baseline LDH 55 adalimumab Humira 55 panitumumab Vectibix 55 hemorrhage arterial thromboembolic 55 polycythemia vera PV 55 dosing cohorts 55 ovarian carcinoma 55 HBeAg + 55 immunomodulatory therapy 55 leukocyte adhesion 55 initiating HUMIRA 55 unresectable 55 Peg IFN 55 #mg/day [001] 55 plasma HCV RNA 55 MULTAQ 55 TELINTRA 55 HER2 overexpression 55 relapsed acute lymphoblastic 55 mm ³ 55 recurrent glioblastoma 55 skeletal metastases 55 neovascularisation 55 evaluating Xcytrin 55 T2DM 55 HBeAg positive patients 55 pg ml 55 TNF antagonist 55 basiliximab 55 advanced metastatic renal 55 q8h 55 taxane chemotherapy administered 55 docetaxel chemotherapy 55 response pCR 55 undetectable hepatitis C 55 chemo radiotherapy 55 pediatric Crohn disease 55 IU ml 55 HER2 positive metastatic breast 55 smoldering myeloma 55 novel histone deacetylase 55 imatinib Gleevec 55 proliferative diabetic retinopathy 55 Severe hypoglycemia 55 nonalcoholic steatohepatitis NASH 55 rituximab refractory 55 generation purine nucleoside 55 relapsing remitting 55 overt hepatic encephalopathy HE 55 Peginterferon Alfa 2a 55 pharmacologically active isomer 55 Thrombotic thromboembolic complications 55 hepatitis C genotype 55 primary immunodeficiency PI 55 pulmonary hypertension PH 55 situ CIS 55 ISTODAX 55 Acute Myeloid Leukemia AML 55 cytidine nucleoside analog 55 neutrophil counts 55 q#d 55 chronic idiopathic 55 colorectal adenoma 55 multiple myeloma MM 55 ALT elevations 55 Telintra 55 nephrotoxicity 55 initiated Phase Ib 55 rALLy clinical trial 55 cetuximab Erbitux ® 55 T#I mutation 55 antiretroviral naive 55 CI #.#-#.# [001] 55 nephrotoxic 55 μmol L 55 weekly intravenous infusions 55 hematological parameters 55 Paraplatin ® 55 XOMA 3AB 55 interferon alfa 2b 55 serum ALT 55 IIb clinical trial 55 tiuxetan 55 metaglidasen 55 histological subtype 55 IV NSCLC 55 highly emetogenic 55 randomized #:#:# 55 KRAS wild 55 treat atopic dermatitis 55 seropositive patients 55 Arch Intern Med 55 antiretroviral naïve 55 Pegasys plus Copegus 55 refractory follicular lymphoma 55 aHUS 55 glioblastoma multiforme GBM 55 Pegasys ® 55 plus OBT 55 QD dosing 55 mitomycin C 55 metastatic bladder 55 μg dose 55 LHRH receptor positive 55 cholecystitis 55 HSCT 55 mg qd 55 pegylated interferon alpha 55 rALLy 55 SHPT 55 R entecavir 55 HCV RESPOND 2 55 nonmetastatic 55 cisplatin chemotherapy 55 endometrial carcinoma 55 diabetic kidney 55 stage IIIb 55 palifermin 55 HGS ETR1 55 Platinol ® cisplatin 55 plus prednisone 55 gemcitabine cisplatin 55 sorafenib tablets 55 opioid induced constipation OIC 55 B lymphocyte 55 Navelbine ® 55 impaired renal 55 Retreatment 55 azilsartan medoxomil 55 detectable HCV RNA 55 GISTs 55 CTAP# Capsules 55 GnRH agonist 55 chemoradiation therapy 55 Anthracycline 55 refractory indolent non 55 relapsing remitting MS RRMS 55 HGPIN 55 indolent NHL 55 neovascular 55 CIMZIA ™ 55 huC# DM4 55 RAEB 54 unresectable locally advanced 54 partial onset seizures 54 virus HCV protease inhibitor 54 ascending dose 54 demonstrated antitumor activity 54 telaprevir dosing 54 subsyndromal 54 plus COPEGUS 54 osteomalacia 54 intravesical therapy 54 undergone splenectomy 54 TRAIL induced apoptosis 54 % CI #.#-#.# [003] 54 diabetes mellitus DM 54 ritonavir boosted 54 receiving ISENTRESS 54 μg ml 54 ORENCIA ® 54 generation PNP inhibitor 54 visilizumab 54 MADRS score 54 follicular Non Hodgkin 54 HIV coinfected 54 emtricitabine tenofovir 54 unresectable hepatocellular carcinoma HCC 54 MYLOTARG 54 unresectable Stage III 54 mRCC 54 J Am Coll 54 castrate resistant 54 e antigen HBeAg 54 idarubicin 54 selectively inhibits 54 #mg/day [002] 54 splenectomized 54 myelodysplastic syndromes 54 KRAS mutant tumors 54 intra articular injection 54 FOLFOX4 alone 54 aged ≥ 54 oxycodone CR 54 TURBT 54 IL 1ß 54 evaluable 54 dose escalation phase 54 refractory SCLC 54 patients coinfected 54 recurrent DVT 54 Chronic Myelogenous Leukemia CML 54 Solid Tumors criteria 54 OMNARIS HFA 54 LymphoStat B TM 54 LEUKINE 54 Mg Uk 54 cells mcL 54 metastatic renal cell carcinoma 54 mg eq 54 CD3 + 54 dosed orally 54 endometrial ovarian 54 lumbar spine BMD 54 baseline neutrophil counts 54 PegIFN 54 administering XIFAXAN 54 progressive PsA 54 malignant pleural mesothelioma MPM 54 cGy 54 neurological manifestations 54 immune thrombocytopenic purpura 54 pmol L 54 gemcitabine carboplatin 54 squamous cell carcinoma SCC 54 ascending doses 54 tirofiban 54 colorectal cancer liver metastases 54 PEG IFN 54 alefacept 54 tumor xenograft models 54 ertapenem 54 portal venous 54 refractory Hodgkin lymphoma 54 tumor regressions 54 OADs 54 #.#ng/ml 54 tolterodine ER 54 octreotide LAR 54 post herpetic neuralgia 54 cyclophosphamide doxorubicin vincristine 54 refractory Ph + 54 endometrial hyperplasia 54 pulmonary exacerbations 54 candidemia 54 cytarabine daunorubicin 54 sUA levels 54 acute decompensation 54 mesangial 54 operable breast cancer 54 irinotecan chemotherapy 54 RGT arm 54 Chronic lymphocytic leukemia 54 dose cytarabine 54 RBC transfusion 54 cells μL 54 MDS AML 54 follicular lymphomas 54 amprenavir 54 trans retinoic acid ATRA 54 Epratuzumab 54 INVEGA ® 54 SinuNase TM 54 ERBITUX therapy 54 #.#/#.# mmHg [001] 54 haematological toxicity 54 metastatic pancreatic 54 Darinaparsin 54 taxane chemotherapy 54 malignant fibrous histiocytoma 54 myelofibrosis 54 Annamycin 54 phase IIb study 54 thrombocytosis 54 Neovascular AMD 54 virologic breakthrough 54 Exacerbations 54 achieved undetectable HCV 54 Phase IIb trials 54 achieve sustained virologic 54 dirucotide MBP# 54 curative resection 54 -#.# log# copies mL 54 hours postdose 54 Gastrointestinal Stromal Tumors 54 pyrazinamide 54 gout flares 54 neutropenic 54 Vaprisol 54 serum urate levels 54 FOLFOX4 54 allograft rejection 54 Hycamtin ® 54 hypersensitivity reaction 54 papillary 54 maintaining Hb 54 cystic fibrosis bronchiectasis 54 Myelodysplastic Syndrome 54 chronic HCV infection 54 HIV HCV coinfected 54 Kidney Int 54 trastuzumab Herceptin R 54 normal ULN 54 FOLPI regimen 54 leukocytosis 54 HER2 expression 54 HIV uninfected 54 symptomatic BPH 54 cEVR 54 hepatic cirrhosis 54 remission CR 54 thrombin inhibiting aptamer 54 dasatinib 54 #mg/kg [002] 54 unresectable stage 54 non metastatic resectable 54 Clinically significant 54 HDAC Inhibitor 54 dacarbazine 53 lamivudine refractory patients 53 REMICADE ® 53 metastatic renal 53 REVIVE Diabetes 53 paroxysmal AF 53 intrahepatic 53 lymphocytic leukemia 53 alpha antagonist 53 dalteparin 53 paragangliomas 53 Phase #/#a trial 53 pulmonary exacerbation 53 diabetic gastroparesis 53 refractory acute myeloid 53 thyroid carcinoma 53 refractory peripheral T 53 undetectable virus HCV 53 relapsed ALL 53 TNF blocker therapy 53 #mg BID [003] 53 ug mL 53 primary humoral immunodeficiency 53 cell carcinoma RCC 53 acute mania 53 drug DMARD 53 EGFR mutation positive 53 myeloproliferative disorders 53 DAS# remission 53 previously untreated follicular 53 neutrophil count 53 treatmentof 53 2A receptor agonist 53 mEq L 53 dopaminergic therapy 53 DOXIL 53 hepatocellular carcinomas 53 resistant ovarian cancer 53 refractory Hodgkin 53 TIMP 1 53 seminoma 53 refractory ovarian cancer 53 Acute Myelogenous Leukemia 53 Barrett esophagus BE 53 MAGE A3 ASCI 53 EVIZON TM 53 ACR# responses 53 budesonide foam 53 baseline A1C 53 mucus plugging 53 rufinamide 53 Scale EDSS score 53 acute leukemias 53 virologically suppressed 53 Index CDAI score 53 Tiuxetan 53 distant metastasis 53 imatinib mesylate 53 Migraine headache 53 herpetic keratitis 53 cervical intraepithelial neoplasia 53 nitrofurantoin 53 non resectable 53 Glioblastoma Multiforme 53 vinorelbine tartrate 53 papillary thyroid carcinoma 53 dose cohorts 53 Irinotecan 53 CANCIDAS 53 Median progression 53 relapsed leukemia 53 macroalbuminuria 53 nodular 53 basal cell nevus syndrome 53 plasma folate 53 anaplastic astrocytoma 53 R abatacept 53 coinfected 53 lumiliximab 53 PREZISTA r 53 thrombotic complications 53 Gleevec imatinib mesylate 53 ug kg 53 evaluating Actimmune 53 indolent follicular non 53 nephritis 53 multicenter randomized placebo controlled 53 Panzem R NCD 53 μg doses 53 prospectively stratified 53 primary peritoneal 53 recurrent ischemia 53 Irritability anxiety cognitive 53 resectable 53 venlafaxine ER 53 5 Fluorouracil 53 cervical lymph nodes 53 vinca alkaloid 53 PASI scores 53 pegylated interferon peg IFN 53 metastatic hormone refractory 53 severe hypoglycaemia 53 gefitinib Iressa 53 fluorouracil leucovorin 53 budesonide pMDI 53 E1 INT TM 53 hA# 53 Index CDAI 53 Evoltra ® 53 3mg/kg 53 5 fluorouracil leucovorin 53 transaminase levels 53 IXEMPRA 53 paclitaxel Taxol R 53 nilotinib 53 toxic megacolon 53 mitoxantrone 53 HBV infections 53 DLBCL 53 receiving APTIVUS r 53 hyperalgesia 53 Response Evaluation Criteria 53 chronic lymphocytic leukemia CLL 53 sorafenib Nexavar ® 53 REYATAZ r 53 peritumoral brain edema 53 cancer neuroendocrine tumor 53 mg/m2 cohort 53 neuropathy sensory 53 Hodgkin lymphoma HL 53 invasive aspergillosis 53 μg mL 53 SinuNase ™ 53 serum potassium levels 53 Sudhir Agrawal D.Phil 53 HCD# [002] 53 serum creatinine levels 53 evaluable patients 53 liposomal formulation 53 severe hypoglycemic 53 esophageal candidiasis 53 B7 H3 53 log# reduction 53 deletion 5q 53 radiotherapy RT 53 Prodarsan 53 cytoreduction 53 placebo dexamethasone 53 squamous cell lung cancer 53 generalized anxiety disorder GAD 53 recurrent ovarian 53 symptomatic VTE 53 haematological malignancies 53 CRp 53 anagrelide 53 bacterial prostatitis 53 TAXOTERE R 53 EDSS scores 53 comparator arm 53 alkylating agents 53 Major Depressive Disorder MDD 53 antiandrogen 53 #mg QD [001] 53 EGFR tyrosine kinase inhibitor 53 Acute Myelogenous Leukemia AML 53 metastatic castrate resistant 53 MabThera Rituxan 53 oblimersen 53 BCG refractory 53 Tarceva TM 53 Emtriva Viread 53 3TC lamivudine Epivir 53 dyskeratosis congenita 53 urine albumin 53 octreotide implant 53 LHRH analogues 53 drugs DMARDs 53 serum calcium levels 53 follicular NHL 53 follicular lymphoma FL 53 basal cell carcinoma BCC 53 refractory MCL 53 undetectable HBV DNA 53 melphalan prednisone 53 iPTH 53 carmustine 53 remitting MS 53 Follicular lymphoma 53 esophageal carcinoma 53 unstable angina UA 53 HBeAg 53 mucosal healing 53 inhaled liposomal ciprofloxacin 53 refractory rituximab naive 53 pegfilgrastim 53 complete remissions 53 hematologic 53 sarcomatoid 53 dysmenorrhoea 53 ceftazidime 53 relapsed MCL 53 Q2W 53 hormone refractory 53 mg orally